The offer of $19.60 a share, represents a premium of 83% on the company’s closing price on Monday, and the board has unanimously recommended that shareholders accept the deal.

https://www.wsj.com/articles/calliditas-therapeutics-gets-1-1-billion-takeover-bid-from-asahi-kasei-dbc7eadc